Sanofi Pasteur Will Fund Development Of Acambis West Nile Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Acambis is hoping to accelerate development of ChimeriVax and be first to market with a West Nile vaccine after inking an agreement with Sanofi Pasteur that includes $10 million upfront and $70 million in milestones.
You may also be interested in...
Acambis Live Smallpox Vaccine Wins FDA Approval
ACAM2000 gained unanimous support of FDA’s Vaccines and Related Biological Products Advisory Committee in May.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.